Anika Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview
10/03/2025 20:26
Anika Therapeutics Inc ANIK.OQ ANIK.O is expected to show a fall in quarterly revenue when it reports results on March 12 for the period ending December 31 2024 The Bedford Massachusetts-based company is expected to report a 32.5% decrease in revenue to $29 million from $42.97 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data. LSEG's mean analyst estimate for Anika Therapeutics Inc is for a loss of 1 cent per share. The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Anika Therapeutics Inc is $26.50, above its last closing price of $16.62. This summary was machine generated March 10 at 20:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)